Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Other Accumulated Expenses (2020 - 2024)

iBio (IBIO) has disclosed Other Accumulated Expenses for 7 consecutive years, with $460000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Other Accumulated Expenses rose 130.0% to $460000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $460000.0, a 130.0% increase, with the full-year FY2024 number at $460000.0, up 130.0% from a year prior.
  • Other Accumulated Expenses was $460000.0 for Q2 2024 at iBio, up from $200000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $460000.0 in Q2 2024 to a low of $136000.0 in Q2 2021.
  • A 5-year average of $238400.0 and a median of $200000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: decreased 18.56% in 2021, then soared 130.0% in 2024.
  • iBio's Other Accumulated Expenses stood at $167000.0 in 2020, then decreased by 18.56% to $136000.0 in 2021, then skyrocketed by 68.38% to $229000.0 in 2022, then dropped by 12.66% to $200000.0 in 2023, then skyrocketed by 130.0% to $460000.0 in 2024.
  • Per Business Quant, the three most recent readings for IBIO's Other Accumulated Expenses are $460000.0 (Q2 2024), $200000.0 (Q2 2023), and $229000.0 (Q2 2022).